Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
ConditionProstate Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18+
SponsorRegion Västerbotten
About this trial
In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.
Eligibility criteria
Qualifiers
Histologically confirmed prostate cancer planned to be treated with radical prostatectomy
PSMA-PET/CT conducted as part of the clinical management for the existing prostate cancer.
≥4 weeks since last biopsy of the prostate
One or more of the following criteria
Disqualifiers
Non-MR-safe implants or another contraindication to MRI or PET
Claustrophobia
Unfit for MRI or PET/MRI examination for any other reason, e.g., back pain
WHO PS >1
Trial design
Treatments tested in this trial
- [18F]PSMA-PET
- MRI sequences optimized for prostate cancer examinations
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Region Västerbotten
Lead sponsor
Umeå University
Collaborator
Region Skane
Collaborator
Lund University
Collaborator
Source ClinicalTrials.gov